Skip to main navigation Skip to search Skip to main content

Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).

  • Anthony B. El-Khoueiry
  • , Zhenggang Ren
  • , Hong Jae Chon
  • , Joon Oh Park
  • , Jin Won Kim
  • , Tiziana Pressiani
  • , Daneng Li
  • , Lyudmila Zhukova
  • , Andrew X. Zhu
  • , Ming Huang Chen
  • , Stephen Paul Hack
  • , Stephanie Wu
  • , Bo Liu
  • , Xiangnan Guan
  • , Shan Lu
  • , Yulei Wang
  • , Teresa Macarulla
  • University of Southern California
  • Fudan University
  • CHA Bundang Medical Center
  • Seoul National University
  • IRCCS Istituto Clinico Humanitas - Rozzano (Milano)
  • City of Hope National Med Center
  • Loginov Moscow Clinical Scientific Center
  • Veterans General Hospital-Taipei
  • Genentech, Inc
  • Vall d'Hebron Institute of Oncology

Research output: Contribution to journalReview articlepeer-review

Fingerprint

Dive into the research topics of 'Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Results from a randomized proof-of-concept phase II trial (IMbrave151).'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Biochemistry, Genetics and Molecular Biology

Immunology and Microbiology

Food Science

Agricultural and Biological Sciences